Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22997176 | 0.84 | ALDH1A1 (0.35) | USP2SMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL24619649 | 0.78 | — | — | |
| SCHEMBL6893345 | 0.77 | ALDH1A1 (0.41) | USP2SMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL24850533 | 0.74 | — | — | |
| SCHEMBL15014396 | 0.74 | ALDH1A1 (0.39) | USP2SMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL16284394 | 0.72 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL18872255 | 0.72 | SMN1; SMN2 (0.36) | USP2SMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL21673295 | 0.72 | L3MBTL1 (0.33) | USP2SMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL8214792 | 0.71 | ALDH1A1 (0.36) | USP2SMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL7945592 | 0.71 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317083-A1 | NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF | CUREVERSE INCORPORATED (KR) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317083-A1 | NOVEL HALO-(3-(PHENYLSULFONYL)PROP-1-ENYL)PYRIDINE DERIVATIVE AND USE THEREOF | KEAP1, NFE2L2, BACH1 | USP2 1762/4885SMN1; SMN2 2773/4885ALDH1A1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.